These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Sialyl residues modulate LPS-mediated signaling through the Toll-like receptor 4 complex. Feng C; Stamatos NM; Dragan AI; Medvedev A; Whitford M; Zhang L; Song C; Rallabhandi P; Cole L; Nhu QM; Vogel SN; Geddes CD; Cross AS PLoS One; 2012; 7(4):e32359. PubMed ID: 22496731 [TBL] [Abstract][Full Text] [Related]
9. Modulation of innate immune responses with synthetic lipid A derivatives. Zhang Y; Gaekwad J; Wolfert MA; Boons GJ J Am Chem Soc; 2007 Apr; 129(16):5200-16. PubMed ID: 17391035 [TBL] [Abstract][Full Text] [Related]
10. Recognition of lipid A variants by the TLR4-MD-2 receptor complex. Maeshima N; Fernandez RC Front Cell Infect Microbiol; 2013; 3():3. PubMed ID: 23408095 [TBL] [Abstract][Full Text] [Related]
11. Recent progress in the discovery of myeloid differentiation 2 (MD2) modulators for inflammatory diseases. Chen L; Fu W; Zheng L; Wang Y; Liang G Drug Discov Today; 2018 Jun; 23(6):1187-1202. PubMed ID: 29330126 [TBL] [Abstract][Full Text] [Related]
12. Human TLR4 polymorphism D299G/T399I alters TLR4/MD-2 conformation and response to a weak ligand monophosphoryl lipid A. Yamakawa N; Ohto U; Akashi-Takamura S; Takahashi K; Saitoh S; Tanimura N; Suganami T; Ogawa Y; Shibata T; Shimizu T; Miyake K Int Immunol; 2013 Jan; 25(1):45-52. PubMed ID: 22962435 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of monophosphoryl lipid A using 2-naphtylmethyl ethers as permanent protecting groups. Verpalen ECJM; Brouwer AJ; Boons GJ Carbohydr Res; 2020 Dec; 498():108152. PubMed ID: 33032087 [TBL] [Abstract][Full Text] [Related]
14. Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2. Kim SY; Koo JE; Seo YJ; Tyagi N; Jeong E; Choi J; Lim KM; Park ZY; Lee JY Br J Pharmacol; 2013 Apr; 168(8):1933-45. PubMed ID: 23231684 [TBL] [Abstract][Full Text] [Related]
15. Lembo-Fazio L; Billod JM; Di Lorenzo F; Paciello I; Pallach M; Vaz-Francisco S; Holgado A; Beyaert R; Fresno M; Shimoyama A; Lanzetta R; Fukase K; Gully D; Giraud E; Martín-Santamaría S; Bernardini ML; Silipo A Front Immunol; 2018; 9():1888. PubMed ID: 30154796 [TBL] [Abstract][Full Text] [Related]
16. The molecular basis of the host response to lipopolysaccharide. Bryant CE; Spring DR; Gangloff M; Gay NJ Nat Rev Microbiol; 2010 Jan; 8(1):8-14. PubMed ID: 19946286 [TBL] [Abstract][Full Text] [Related]
17. Lipid A from lipopolysaccharide recognition: structure, dynamics and cooperativity by molecular dynamics simulations. Garate JA; Oostenbrink C Proteins; 2013 Apr; 81(4):658-74. PubMed ID: 23184816 [TBL] [Abstract][Full Text] [Related]
19. The attenuated inflammation of MPL is due to the lack of CD14-dependent tight dimerization of the TLR4/MD2 complex at the plasma membrane. Tanimura N; Saitoh S; Ohto U; Akashi-Takamura S; Fujimoto Y; Fukase K; Shimizu T; Miyake K Int Immunol; 2014 Jun; 26(6):307-14. PubMed ID: 24380872 [TBL] [Abstract][Full Text] [Related]
20. Chemical Hybridization of Vizantin and Lipid A to Generate a Novel LPS Antagonist. Yamamoto H; Oda M; Kanno M; Tamashiro S; Tamura I; Yoneda T; Yamasaki N; Domon H; Nakano M; Takahashi H; Terao Y; Kasai Y; Imagawa H Chem Pharm Bull (Tokyo); 2016; 64(3):246-57. PubMed ID: 26725501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]